Research Funding

Open opportunities and active NIH grants in structural heart and prosthetic valves

Open Opportunities

1 active
Federal9d left

NHLBI Stimulating Peripheral Activity to Relieve Conditions (SPARC)

National Heart, Lung, and Blood Institute (NIH)

NHLBI funding opportunities for cardiovascular device development including transcatheter and surgical valve technologies.

Varies
Deadline: Dec 1, 2026
US investigators
View opportunity

Funded Research

4 active grants · $5.5M total

Filter by Topic

Clear filters

Data from NIH Reporter. Updated weekly.

R01FY2026Mitral
$3.6M
EVOLVE-MR: Extending Valve-Surgery Outcomes from Landmark Trials to Varied Everyday Patients with Mitral Regurgitation
SUAREZ-FARINAS, MAYTE
ends May 31, 2030

PROJECT SUMMARY (Abstract) Valvular heart disease (VHD) is a leading cause of heart failure, morbidity, and mortality in the United States, affecting more than 13 million adults and one in ten individuals older than 75 years. Landmark randomized clinical trials (RCTs) from the Cardiothoracic Surgical Trials Network (CTSN) have defined modern surgical practice, yet despite their methodological rigor and impact on guidelines, these trials enrolled a subset of patients, typically younger, healthier, and treated at high-volume academic centers over a relatively short (≤24-month) follow-up. As a result, their findings may not generalize to the older, multimorbid, and diverse populations who undergo valve surgery in real-world practice. This proposal addresses a fundamental limitation of surgical evidence—the gap between causal rigor and clinical representativeness. Guided by the CAROL Act mandate to accelerate evidence generation in VHD, we will integrate CTSN randomized trials with longitu

R01FY2026Mitral
$778K
Improving Phenotypic Classification and Prediction of Treatment Outcomes in Patients with Non-ischemic Cardiomyopathy and Functional Mitral Regurgitation
KWON, DEBORAH
ends Apr 30, 2028

Project Summary Functional mitral regurgitation (FMR) portends a bleak prognosis and is a common consequence of ischemic and non-ischemic cardiomyopathy (ICM, NICM), where adverse annular and left ventricular (LV) remodeling and/or infarction alters mitral valve (MV) function. Prior studies demonstrate significant increases in mortality risk as severity of FMR increases; mortality rates range from 15-40% at 1 year. Furthermore, as the prevalence of heart failure (HF) is rising, FMR is projected to double from over 2 million patients in 2000 to over 4 million patients in the United States by 2030. Defining FMR severity, optimal timing of intervention, and most appropriate method for intervention remain controversial. Recently, MITRA-FR and COAPT trials demonstrated contrasting survival benefit with percutaneous MV repair, demonstrating the importance and need for more optimal selection criteria. Currently, the patient selection criteria for Mitraclip therapy are solely based on MV anat

R01FY2026Mitral
$582K
Mechanism of Eccentric Cardiomyocyte Hypertrophy Secondary to Mitral Regurgitation
DRAKOS, STAVROS GEORGE
ends Apr 30, 2027

Valvular heart disease represents a major public health problem worldwide. The incidence of valvular heart disease increases with age, and it is estimated that about 15% of the population above the age of 75 years suffer from some form of significant valvular disorder. Mitral regurgitation (MR) is the most frequent form of valvular heart diseases, where it is estimated that moderate and severe MR occurs at a frequency of 1.7% as adjusted to the US adult population, and up to 5% of the population in Europe have significant mitral valve disease. The natural history of chronic MR is characterized by a compensated hemodynamic state in its early phases, followed by a gradual progressive left ventricular (LV) remodeling and eccentric hypertrophy resulting in heart failure. MR patients with depressed systolic function can present a difficult management dilemma; corrective valve surgery is not recommended, and medical therapy is ineffective in preventing LV dysfunction. It should perhaps be no

R01FY2026Mitral
$549K
Reciprocal effects between scaffold geometry and ventricular vortex flow on viability and performance of tissue-engineered mitral valve
KHERADVAR, ARASH
ends Dec 31, 2027

PROJECT SUMMURY/ABSTRACT Valvular heart disease (VHD) is the third-most common cause of heart problems in the United States, with mitral valve disease as the second-most common VHD after aortic stenosis. Mitral valve disease can cause many complications if left untreated and is more common in younger patients, in whom bioprosthetic heart valves (BHVs) are prone to faster degeneration. An ultimate solution for younger patients with long life expectancy is a living tissue valve, although exploratory studies for tissue-engineered heart valve (TEHVs) have yet to satisfy the regulatory requirements for clinical use. In preclinical studies, current TEHVs have been unable to adjust their composition to withstand the hemodynamic loads to which they would be exposed, and their leaflets were found to shrink due to their degradable scaffolds, which led to poor leaflet coaptation, followed by progressive regurgitation and valvular insufficiency. The native mitral valve is bileaflet, with a saddle-